Pipeline

Built on our proprietary ImmTAX platform, we have a diverse pipeline of bispecific therapies across a broad range of indications.

Our pipeline includes clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects

Tebentafusp

/ Target: gp100 (A02)

Adjuvant uveal (ocular)
melanoma

ATOM sponsored by EORTC

IND-enabling
Phase 1
Phase 2
Phase 3
Phase 3 ongoing

2L+ advanced cutaneous melanoma

TEBE-AM

IND-enabling
Phase 1
Phase 2
Phase 3
Phase 3 enrollment completion | 1H 2026

Brenetafusp (IMC-F106C)

/ Target: PRAME (A02)

1L advanced cutaneous melanoma

PRISM-MEL-301

IND-enabling
Phase 1
Phase 2
Phase 3
Phase 3 ongoing
Phase 1/2

Ovarian1

IND-enabling
Phase 1
Phase 2
Phase 3
Phase 1/2 ongoing

NSCLC2

IND-enabling
Phase 1
Phase 2
Phase 3

Additional solid tumors

IND-enabling
Phase 1
Phase 2
Phase 3

IMC-P115C

/ Target: PRAME-HLE (A02)

Multiple solid tumors

IND-enabling
Phase 1
Phase 2
Phase 3
Phase 1/2 ongoing

IMC-T119C

/ Target: PRAME (A24)

Multiple solid tumors

IND-enabling
Phase 1
Phase 2
Phase 3

IMC-R117C

/ Target: PIWIL1 (A02)

Colorectal and GI cancers

IND-enabling
Phase 1
Phase 2
Phase 3
Phase 1/2 ongoing

IMC-M113V<sup>3</sup>

/ Target: Gag (A02)

Human Immunodeficiency Virus (HIV)

IND-enabling
Phase 1
Phase 2
Phase 3
MAD Data | 1Q 2025

IMC-I109V

/ Target: Envelope (A02)

Hepatitis B Virus (HBV)

IND-enabling
Phase 1
Phase 2
Phase 3
SAD Data | 2025

IMC-S118AI

/ Target: PPI (A02)

Type 1 Diabetes

IND-enabling
Phase 1
Phase 2
Phase 3
CTA/IND submission | 4Q 2025

IMC-U120AI

/ Target: CD1a (non-HLA restricted)

Dermatology

IND-enabling
Phase 1
Phase 2
Phase 3
CTA/IND submission | 2026
Date last updated: January 2025
1 Platinum refractory or resistant serous ovarian carcinoma. 2 NSCLC = Non-small cell lung cancer. 3 Program is wholly owned, development costs being provided by the Bill & Melinda Gates Foundation (BMGF), Immunocore retains all development and commercialization rights in the developed world. 

KIMMTRAK

KIMMTRAK approved for HLA-A*02:01–positive metastatic or unresectable uveal melanoma

Disclaimer

All trademarks, company and product names or logos are the property of their respective owners. The efficacy and safety of the molecules under investigation have not yet been established. There is no guarantee that pipeline molecules will receive approval and become commercially available for the uses being investigated as drug development is uncertain and agents in development may be terminated along the development process. The above information is accurate as of September 2024.